Pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 10, 1999, Pages 2409-2411

  Breilh, Dominique ^a   Allaouchiche, Bernard ^b   Jaumain, Hélène ^c   Bouletreau, Paul ^c   Chassard, Dominique ^b   Malbec, Isabelle ^a   Ducint, Dominique ^a   Saux, Marie Claude ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISEPAMICIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0032821148     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.10.2409     Document Type: Article

References (16)

1. Barr, W. H., R. Colucci, E. Radwanski, N. Zampaglione, D. Cutler, C. C. Lin, M. Elliott, and M. B. Affrime. 1995. Pharmacokinetics of isepamicin. J. Chemother. 7:53-61.
2. Bressolle, F., J. M. Kinowski, J. E. de la Coussaye, N. Wynn, J. J. Eledjam, and M. M. Galtier. 1994. Clinical pharmacokinetics during continuous haemofiltration. Clin. Pharmacokinet. 26:457-471.
3. Cotterill, S. 1995. Antimicrobial prescribing in patients on haemofiltration. J. Antimicrob. Chemother. 36:773-780.
4. D'Argenio, D. 1981. Optimal sampling times for pharmacokinetics experiments. J. Pharmacokinet. Biopharm. 9:739-756.
5. Davies, J., J. Kingswood, P. Sharpstone, and M. Street. 1995. Drug removal in continuous haemofiltration and haemodialysis. Br. J. Hosp. Med. 54:524-528.
6. Geronemus, R. P., N. S. Schneider, and M. Epstein. 1991. Survival in patients treated with continuous arteriovenous haemodialysis for acute renal failure and chronic renal failure. Contrib. Nephrol. 93:29-31.
7. Golper, T. A. 1993. Drug removal during continuous renal replacement therapies. Dial. Transplant. 22:185-188.
8. Halstenson, C. E., J. S. Kelloway, M. B. Affrime, C. C. Lin, M. A. Teal, B. E. Shapiro, and W. M. Awni. 1991. Isepamicin disposition in subjects with various degrees of renal function. Antimicrob. Agents Chemother. 35:2382-2387.
9. Jones, R. N. 1995. Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. J. Chemother. 7:7-16.
10. Mentré, F., and R. Gomeni. 1995. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J. Biopharm. Stat. 5:141-158.
11. Reetze-Bonorden, P., J. Böhler, and E. Keller. 1993. Drug dosage in patients during continuous renal replacement therapy. Clin. Pharmacokinet. 24:362-379.
12. Shetz, M., P. Ferdinande, G. Van den Berghe, C. Verwaest, and P. Lauwers. 1995. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med. 21:612-620.
13. Suzuki, K., M. Horiba, and Y. Nagata. 1990. Pharmacokinetic and clinical studies on isepamicin in chronic complicated urinary tract infection using daily single dose treatment. Jpn. J. Antibiot. 43:1649-1659.
14. Tam, P. Y., S. Huraib, B. Mahan, D. LeBlanc, C. A. Lunski, C. Holtzer, C. E. Doyle, S. I. Vas, and P. R. Uldall. 1988. Slow continuous hemodialysis for the management of complicated acute renal failure in an intensive care unit. Clin. Nephrol. 30:79-85.
15. Tod, M., C. Padoin, C. Minozzi, J. Cougnard, and O. Petitjean. 1996. Population pharmacokinetic study of isepamicin with intensive care unit patients. Antimicrob. Agents Chemother. 40:983-987.
16. Uematsu, T., A. Mizuno, Y. Suzuki, R. Sato, T. Yamazaki, and M. Nakashima. 1988. Evaluation of a fluorescence polarization immunoassay procedure for quantification of isepamicin, a new aminoglycoside antibiotic. Ther. Drug Monit. 10:459-462.